2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, there have been several randomized controlled trials that should change patient management ahead of the next scheduled full guideline. This 2023 Focused Update addresses changes in recommendations for the treatment of HF because of this new evidence. We considered new  published evidence up until the 31 March 2023. After considering and discussing many new  major randomized controlled clinical trials and meta-analyses, the Task Force voted to include those that would lead to Class IIa and I recommendations. This has led to us updating some of our guidance for the treatment of HFmrEF, HFpEF, comorbidities and Acute HF.